Photo by Glsun Mall on Unsplash
Roche Enters Obesity Market Through Carmot Therapeutics Acquisition
December 6, 2023
Swiss pharma company Roche recently announced a strategic $2.7 billion deal to acquire U.S.-based Carmot Therapeutics, indicating its entry into the obesity market.
Roche will pay the sum in cash upon closing and may provide further milestone payments of up to $400 million to equity holders. The acquisition allows Roche access to the obesity sector and Carmot’s unique portfolio of incretins: CT-388, CT-996, and CT-868. These incretins are under various stages of research for obesity treatment for patients with or without type 2 diabetes. The portfolio might extend to include conditions such as cardiovascular, retinal, and neurodegenerative diseases.
In addition to Carmot’s incretin portfolio, Roche will secure exclusive access to its novel Chemotype Evolution discovery platform, bolstering its research and development efforts in cardiovascular and metabolic diseases. Despite the promising acquisition, Roche’s shares have declined by 12.2% YTD, contrasting with the industry’s 4.8% growth.
The obesity market has lately been a hotbed of interest, fueling drugs like Novo Nordisk’s Wegovy and Eli Lilly’s Mounjaro (tirzepatide), among others. Wegovy has seen remarkable demand on the global stage, bolstering Novo Nordisk. On the other hand, Mounjaro, approved in 2022, improves glycemic control in adults with type 2 diabetes when combined with diet and exercise. The FDA recently approved tirzepatide, branded as Zepbound, for adults struggling with obesity or overweight issues, alongside weight-related health conditions like hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea, or cardiovascular disease.
However, the obesity market isn’t without its challenges. Pfizer recently experienced a disappointment after its weight loss pill, danuglipron, exhibited side effects in its phase III studies. Despite significant reductions in body weight, the study recorded high rates of gastrointestinal side effects, resulting in high discontinuation rates and the consequent decision by Pfizer not to progress with danuglipron.
Recent News
Media Giants Depend on Sports As Content Shortages Rise
As Hollywood emerges from last year’s strikes, major media companies are turning to live sports to attract audiences and advertisers. This trend was evident during this year’s Upfront presentations, where media giants showcased their upcoming content and advertising opportunities.
New Trader Joe’s Opens in SF After 10 Years
San Francisco’s Hayes Valley neighborhood welcomed a highly anticipated new addition on May 17, 2024, with the grand opening of a Trader Joe’s at 555 Fulton St., on the corner of Laguna Street. This event marks the end of a decade-long wait for residents who have been eagerly looking forward to a new grocery store in their area.
China’s Property Market Boost: Stocks Surge, Copper Hits Highs
The Chinese government unveiled a comprehensive support package that has sent ripples through financial markets. This initiative includes a slew of measures aimed at stimulating housing demand and addressing the excess inventory burdening developers. The immediate impact was a significant rally in Chinese stocks and a surge in commodity prices, notably copper, which hit record highs.
Mercedes-Benz Workers in Alabama Reject Union
In a pivotal moment for autoworkers in the southern United States, employees at a Mercedes-Benz plant in Alabama have voted against joining the United Auto Workers (UAW) union. The outcome, with 56% of workers voting against unionization and 44% in favor, comes as a significant setback for the UAW’s efforts to expand its influence in the region.